We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+8.51%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$342M
AUM Growth
+$89.9M
Cap. Flow
+$78.3M
Cap. Flow %
22.9%
Top 10 Hldgs %
35.24%
Holding
113
New
44
Increased
16
Reduced
11
Closed
37

Top Buys

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$9.51M
2
DXCM icon
DexCom
DXCM
+$8.48M
3
AGN
Allergan plc
AGN
+$8.14M
4
CNC icon
Centene
CNC
+$6.89M
5
INCY icon
Incyte
INCY
+$6.33M

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$10M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$8.72M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$6.55M
4
NXTM
NxStage Medical Inc.
NXTM
+$5.56M
5
QGENF
QIAGEN NV
QGENF
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 49.95%
2 Industrials 2.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVEO
101
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-10,000
Closed -$222K
ARRY
102
DELISTED
Array Biopharma Inc
ARRY
– –
-265,589
Closed -$2.22M
ADYX
103
DELISTED
Adynxx Inc
ADYX
– –
-20,134
Closed -$447K
HZNP
104
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-150,000
Closed -$1.78M
WMGIZ
105
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
-587,241
Closed -$857K
NXTM
106
DELISTED
NxStage Medical Inc.
NXTM
– –
-221,685
Closed -$5.56M
TSRO
107
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-13,100
Closed -$1.83M
TSRO
108
DELISTED
TESARO, Inc.
TSRO
– –
-29,900
Closed -$4.18M
ABCO
109
CALL
DELISTED
Advisory Board Co
ABCO
– –
-4,400
Closed -$227K
ABCO
110
DELISTED
Advisory Board Co
ABCO
– –
-100,000
Closed -$5.15M
NDRM
111
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-70,000
Closed -$2.09M
QGENF
112
DELISTED
QIAGEN NV
QGENF
– –
-156,900
Closed -$5.26M
1 2 3 4
5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q3 2017 Portfolio in Review

As of Q3 2017, Pura Vida Investments held 113 positions worth $342M, up 36% from $252M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments deployed $78.3M of net new capital in Q3 2017, opening 44 new positions and adding to 16 existing holdings. Its largest new stake was Dentsply Sirona: 160,000 shares worth $9.57M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 66% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $8.72M trimmed.

  • Pura Vida Investments's largest Q3 2017 buy was Dentsply Sirona: 160,000 shares worth $9.57M.
  • Pura Vida Investments added most to Athenahealth, Inc. in Q3 2017, an estimated $2.31M increase.
  • Pura Vida Investments's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $8.72M.
  • Pura Vida Investments fully exited Labcorp in Q3 2017, selling an estimated $10M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $342M portfolio in Q3 2017.
  • Pura Vida Investments opened 44 new positions and closed 37 in Q3 2017.
  • Pura Vida Investments's portfolio value rose 36% quarter-over-quarter to $342M.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.